INS and type 1 diabetes mellitus: Nevertheless, after a century of almost exclusive reliance on insulin therapy for the treatment of T1D, novel immunotherapies are now focused on immunomodulation for patients with pre-symptomatic disease (stages 1 and 2 T1D) and for patients with newly diagnosed (symptomatic) disease (stage 3 T1D) [2].